Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial

Background Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis. Methods Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5–5 mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo. Secondary endpoints included radiological progression, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and knee pain. The trial is registered (ISRCTN41323372). Results The intention-to-treat population included 1371 patients. Treatment with strontium ranelate was associated with smaller degradations in JSW than placebo (1 g/day: −0.23 (SD 0.56) mm; 2 g/day: −0.27 (SD 0.63) mm; placebo: −0.37 (SD 0.59) mm); treatment-placebo differences were 0.14 (SE 0.04), 95% CI 0.05 to 0.23, p<0.001 for 1 g/day and 0.10 (SE 0.04), 95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer radiological progressors were observed with strontium ranelate (p<0.001 and p=0.012 for 1 and 2 g/day). There were greater reductions in total WOMAC score (p=0.045), pain subscore (p=0.028), physical function subscore (p=0.099) and knee pain (p=0.065) with strontium ranelate 2 g/day. Strontium ranelate was well tolerated. Conclusions Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure in patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day.

[1]  H. Namazi.  Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial , 2012, Current medical research and opinion.

[2]  C. Cooper,et al.  Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial , 2012, Current medical research and opinion.

[3]  A. Mobasheri,et al.  IGF-1 and PDGF-bb Suppress IL-1β-Induced Cartilage Degradation through Down-Regulation of NF-κB Signaling: Involvement of Src/PI-3K/AKT Pathway , 2011, PloS one.

[4]  J. Pelletier,et al.  Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. , 2011, Bone.

[5]  F. Berenbaum,et al.  Osteoarthritis: an update with relevance for clinical practice , 2011, The Lancet.

[6]  C. Cooper,et al.  Excess mortality in osteoarthritis , 2011, BMJ : British Medical Journal.

[7]  P. Ravaud,et al.  Influence of blinding sequence of radiographs on the reproducibility and sensitivity to change of joint space width measurement in knee osteoarthritis , 2010, Arthritis care & research.

[8]  D. Reda,et al.  Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT , 2010, Annals of the rheumatic diseases.

[9]  P Tugwell,et al.  OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. , 2010, Osteoarthritis and cartilage.

[10]  Johanne Martel-Pelletier,et al.  Targeting subchondral bone for treating osteoarthritis: what is the evidence? , 2010, Best practice & research. Clinical rheumatology.

[11]  P. Halbout,et al.  Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response , 2009, Osteoporosis International.

[12]  P. Delmas,et al.  Radiologic assessment of age-related knee joint space changes in women: a 4-year longitudinal study. , 2009, Arthritis and rheumatism.

[13]  M. Nevitt,et al.  Blinding images to sequence in osteoarthritis: evidence from other diseases. , 2009, Osteoarthritis and cartilage.

[14]  J. Reginster,et al.  Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. , 2009, Arthritis and rheumatism.

[15]  D. Reda,et al.  The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. , 2008, Arthritis and rheumatism.

[16]  J. Caverzasio.  Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. , 2008, Bone.

[17]  S. Bilgili,et al.  The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study , 2008, Archives of Gynecology and Obstetrics.

[18]  T. Spector,et al.  Effects of strontium ranelate on spinal osteoarthritis progression , 2007, Annals of the rheumatic diseases.

[19]  T. Spector,et al.  Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. , 2006, Arthritis and rheumatism.

[20]  F. Breedveld,et al.  Reading radiographs in pairs or in chronological order influences radiological progression in osteoarthritis. , 2005, Rheumatology.

[21]  L. Sharma,et al.  Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. , 2005, Arthritis and rheumatism.

[22]  J. Reginster,et al.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.

[23]  J. Reginster,et al.  Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study , 2005, Annals of the rheumatic diseases.

[24]  E. Vignon,et al.  Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[25]  C. Peterfy,et al.  Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis , 2004, European Radiology.

[26]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[27]  K. Pavelka,et al.  Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. , 2002, Archives of internal medicine.

[28]  D O Slosman,et al.  Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  C. Cooper,et al.  Knee osteoarthritis and obesity , 2001, International Journal of Obesity.

[30]  J. Reginster,et al.  Strontium Ranelate Increases Cartilage Matrix Formation , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  Eric Lejeune,et al.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial , 2001, The Lancet.

[32]  D. Felson,et al.  Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. , 2000, The Journal of rheumatology.

[33]  C. Cooper,et al.  Risk factors for the incidence and progression of radiographic knee osteoarthritis. , 2000, Arthritis and rheumatism.

[34]  H. Valkenburg,et al.  Do clinical findings associate with radiographic osteoarthritis of the knee? , 1990, Annals of the rheumatic diseases.

[35]  C. Goldsmith,et al.  Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. , 1988, The Journal of rheumatology.

[36]  R. Moskowitz,et al.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.

[37]  C. Dunnett.  A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .

[38]  T. Spector,et al.  Genetic epidemiology of hip and knee osteoarthritis , 2011, Nature Reviews Rheumatology.

[39]  S. Haque.  Ethics approval This study was conducted with the approval of the East London and City Health Authority Ethic Committee. Provenance and peer review Not commissioned; externally peer reviewed. , 2011 .